SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilBigKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 9/22/2017 12:24:35 AM - Followers: 717 - Board type: Free - Posts Today: 4

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 09/11/2017 06:04:37 AM
IPIX News: Statement of Changes in Beneficial Ownership (4) 09/06/2017 06:27:18 PM
IPIX News: Statement of Changes in Beneficial Ownership (4) 09/06/2017 06:24:45 PM
PostSubject
#197146  Sticky Note 4th Quarter catalysts approaching BooDog 09/16/17 07:09:34 AM
#196902  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/14/17 06:23:42 PM
#196731  Sticky Note I sent this artilce to Leo,.... looks like cabel 09/14/17 08:36:29 AM
#196630  Sticky Note Proof of Concept (PoC) studies -- the exact slcimmuno 09/13/17 12:06:33 PM
#191428  Sticky Note $IPIX - Innovation Pharmaceuticals Stock May Be A LilBigKahuna 07/23/17 12:25:32 AM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#197828   "KEVETRIN CAN LEAD TO A GROUNDBREAKING MOMENT IN LilBigKahuna 09/22/17 12:24:35 AM
#197827   "Cellceutix believes that this clinical trial, using IV Blue Fin 09/22/17 12:22:51 AM
#197826   deleted Blue Fin 09/22/17 12:02:05 AM
#197825   Hmmmmm, Maybe something is happening, the primary purpose Blue Fin 09/22/17 12:02:04 AM
#197823   This was 5 years back - nothing has Amatuer17 09/21/17 09:49:25 PM
#197822   Strong endorsement by Dr. Frei indeed. The preclinical sox040713 09/21/17 08:11:17 PM
#197821   2017 has been the year where partnership opportunities nerby 09/21/17 08:10:59 PM
#197820   IPIX and Kevetrin - it's potential prized blockbuster tryz 09/21/17 08:03:40 PM
#197819   Thanks for reminding this important point. "But, conversely, a sox040713 09/21/17 07:55:17 PM
#197818   Meant headline to the article not your post scottsmith 09/21/17 07:40:24 PM
#197817   I've never been in the habit of previewing BooDog 09/21/17 07:38:41 PM
#197816   http://www.prnewswire.com/news-releases/cellceutix-reports-confidential-disclosu Blues44 09/21/17 07:38:34 PM
#197815   Funny to read the very declarative headline compared scottsmith 09/21/17 07:26:11 PM
#197814   Holy Grail-Used in biotech to describe things that Blues44 09/21/17 07:11:08 PM
#197813   thanks Sox. TheHound 09/21/17 07:10:58 PM
#197810   Thinking if Dr. Frei were still alive he'd BooDog 09/21/17 06:37:12 PM
#197809   11. I read on an internet chat room sox040713 09/21/17 06:37:12 PM
#197808   FINRA short sales of IPIX AlanC 09/21/17 06:30:09 PM
#197807   Another good article on p53. sox040713 09/21/17 06:19:43 PM
#197806   https://static1.squarespace.com/static/5715352e20c647639137f992/t/59c11a20d7bdcedc158226a2/150582736 TheHound 09/21/17 06:09:07 PM
#197805   I don't mean five years ago. I remember sox040713 09/21/17 06:08:40 PM
#197804   I referenced that article when I had drank Amatuer17 09/21/17 05:51:29 PM
#197803   disinformation. TheHound 09/21/17 05:40:26 PM
#197802   Some think so. I think more like around septmike09 09/21/17 05:36:32 PM
#197801   Does anyone really think we will see a snayeman 09/21/17 05:11:27 PM
#197800   Great book. p53 is so deep in the frrol 09/21/17 05:09:05 PM
#197799   I find it ironic that you referenced this sox040713 09/21/17 05:05:50 PM
#197798   Well and so what? Why they will turn to Amatuer17 09/21/17 04:52:17 PM
#197797   That's a novel idea - help it get rule_rationale 09/21/17 04:49:19 PM
#197796   In reality - you can name only 3 Amatuer17 09/21/17 04:49:09 PM
#197795   A lot has happened clinically in the past KarinCA 09/21/17 04:42:24 PM
#197794   stuck in the ditch...wheels spinning...needs a push! noretreat 09/21/17 04:41:16 PM
#197793   The volume of the trading day before Protagonist sox040713 09/21/17 04:34:55 PM
#197792   Amatuer17 They are getting hit with law suits in Echo20 09/21/17 04:32:50 PM
#197789   IPIX hasn't failed a trial yet. Dr. Menon sox040713 09/21/17 04:16:57 PM
#197788   He needs gains to offset groton68 09/21/17 04:05:20 PM
#197786   Ouch. You should sell and write it off septmike09 09/21/17 04:02:18 PM
#197785   I don't agree with your analogy and I sox040713 09/21/17 04:01:45 PM
#197784   6 digits MXAMDUD 09/21/17 04:01:03 PM
#197781   yet another sh!t rotten IPIX trading day. MXAMDUD 09/21/17 03:52:04 PM
#197779   I think more accurately its primary purpose is frrol 09/21/17 03:21:16 PM
#197778   MXAM, you're efforts are admirable but fruitless. taas 09/21/17 02:53:04 PM
#197777   This is a time to accumulate. Efficient market groton68 09/21/17 02:34:07 PM
#197776  Restored you're efforts are admirable but fruitless. thanks MXAMDUD 09/21/17 02:33:58 PM
#197775   I added and bought another 10k today in tryz 09/21/17 02:29:29 PM
#197774   Probably realized it was not a good move. TheBunny 09/21/17 02:26:59 PM
#197773   yes but he's been correct - look at MXAMDUD 09/21/17 02:26:29 PM
#197772   And the 100k shares ask order disappeared... romaa 09/21/17 02:23:44 PM
#197771   'Showing' a 100K sell offer, on a thinly TheBunny 09/21/17 02:22:32 PM
#197770   Knowing how the market makers like to "fake BooDog 09/21/17 02:09:16 PM
PostSubject